About us
Making brain health measurable at scale
Cognitive function underpins how we think, learn and experience the world.
It is a critical indicator of psychiatric, neurodevelopmental and degenerative conditions, yet it remains one of the most difficult areas of health to measure reliably and meaningfully.
Backed by over 40 years of research, 3,600+ peer-reviewed publications and use in more than 600 clinical trials, our digital and voice-based assessments are trusted by academics, clinical teams, healthcare professionals and consumers brands to detect meaningful changes in cognition and enable informed decision-making.
Our story
The Cambridge Neuropsychological Test Automated Battery (CANTAB®) is developed by Professor Barbara Sahakian and Professor Trevor Robbins at the University of Cambridge.
Cambridge Cognition Ltd was spun out of the University of Cambridge to commercialise the CANTAB technology.
CANTAB Mobile is launched, a tablet-based cognitive assessment tool for healthcare.
Cambridge Cognition Ltd goes public on the AIM market of the London Stock Exchange.
Winterlight Labs is founded in Toronto, Canada by Frank Rudzicz, Katie Fraser, Liam Kaufman and Maria Yancheva.
Launch of Cognition Kit™ for high-frequency testing on wearable devices such as smartwatches and fitness trackers.
Virtual clinical trial solutions extended including remote patient monitoring, electronic informed consent and online data capture through the acquisition of eClinical Health.
Cambridge Cognition and Winterlight Labs join forces to lead in voice and digital biomarkers for clinical trials.
CANTAB Pathway™ launched for use in consumer and healthcare settings as a trusted journey from screening to understanding and monitoring brain health.
Who we work with
Supporting academic research through neuropsychological testing technologies, our solutions enable the discovery and enhanced understanding of factors in our biology and environment that affect cognitive function. We have facilitated the advancement of research across the world at top-ranking universities.
We offer a comprehensive solution for assessing cognitive safety and efficacy of drugs in development, from assessment technologies to study delivery. GCP compliant and suitable for use throughout all phases of clinical development, we combine leading scientific software with expert support, trusted by global pharmaceutical companies.
Our suite of healthcare technology solutions are designed to detect the earliest signs of clinically relevant memory problems, measure cognitive performance and assess wellbeing, in primary care and workplace settings, bringing cognitive assessments to patients and employees where they are.
Cambridge Cognition in numbers
indications assessed using our technologies
patients assessed on our digital health tools
peer reviewed papers & articles
patient engagement
Countries
of our customers would recommend us
Senior Leadership Team
Rob Baker
Chief Executive Officer
Ronald Openshaw
Chief Financial Officer
Dr Francesca Cormack
Chief Scientist
Ricky Dolphin
Chief Technology Officer
Will Harrison
Director of Commercial Operations
Liam Kaufman
EVP Product
Becca Day
Head of People
Careers
We are always looking for the best talent to join our growing team. Learn what it is like to work at Cambridge Cognition and find your next role.
Charity of the Year
Every year we select a charity to support, raising money through social activities, physical challenges, and volunteering opportunities. We are especially passionate about supporting charities that promote mental wellbeing and who provide support for people affected by neurological disorders – both the patients themselves and their families.
